Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein
degradation tool developed in recent years that can ubiquitinate the target proteins through …

Molecular targeted therapies are revolutionized therapeutics which interfere with specific
molecules to block cancer growth, progression, and metastasis. Many molecular targeted …

Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …

Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …